The potential utility of arterial spin labeling in predicting brain amyloidosis

IF 1.9 4区医学 Q3 CLINICAL NEUROLOGY

Journal of Clinical Neuroscience Pub Date : 2025-05-05 DOI:10.1016/j.jocn.2025.111248

Kimia Kazemzadeh , Nasim Naseri , Mahsa Mombeini , Amirhossein Khodadadi , Mina Jafari , Rezvaneh Rostami , Parisa Enayat , Maryam Sadeghi , Soorin Berenjian , Seyed Mohammad Amin Alavi

{"title":"The potential utility of arterial spin labeling in predicting brain amyloidosis","authors":"Kimia Kazemzadeh , Nasim Naseri , Mahsa Mombeini , Amirhossein Khodadadi , Mina Jafari , Rezvaneh Rostami , Parisa Enayat , Maryam Sadeghi , Soorin Berenjian , Seyed Mohammad Amin Alavi","doi":"10.1016/j.jocn.2025.111248","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div> The study included 140 participants from theAlzheimer’sDisease Neuroimaging Initiative (ADNI), comprising 43 cognitively normal (CN) individuals, 70 patients with mild cognitive impairment (MCI), and 27 withAlzheimer’sdisease (AD). Eligible participants had comprehensive assessments of cognition, ASL, Apolipoprotein E4 (APOE4) genotyping, Polygenic Hazard Score (PHS) calculation, and amyloidosis indices. Datawere analyzedusing IBM SPSS ver. 20, employing chi-square, ANOVA, and linear regression models, with a significance threshold of P < 0.05.</div></div><div><h3>Results</h3><div>There were no statistically significant differences in demographic characteristics, including age, gender, and education level. Significant differences emerged in amyloid beta-protein 42 (Aβ42) levels, APOE4 status, and cognitive performance across groups. Four brain regions, including the left middle temporal, bilateral <em>para</em>-hippocampal, and right lingual cortex exhibited significant CBF differences (p < 0.05). Clinical Dementia Rating (CDR) correlated strongly with various brain regions, particularly in MCI individuals. Moreover, CBF in multiple regions showed significant associations with Aβ variants and their ratios, especially Aβ42, even after adjusting for confounding factors.</div></div><div><h3>Conclusion</h3><div> <!-->ASL demonstrates potential in predicting brain amyloidosis and monitoring AD. Significant associations between CBF and amyloid-beta levels suggest that ASL can detect early perfusion deficits related to AD progression.</div></div>","PeriodicalId":15487,"journal":{"name":"Journal of Clinical Neuroscience","volume":"137 ","pages":"Article 111248"},"PeriodicalIF":1.9000,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Neuroscience","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0967586825002206","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Declines in regional cerebral blood flow (rCBF) are common in Alzheimer’s disease. Previous studies have linked higher amyloid beta-protein (Aβ) loads, detected by Positron Emission Tomography (PET), with rCBF in normally aging individuals. This study aims to assess the potential of Arterial Spin Labeling (ASL) in predicting brain amyloidosis.

Methods

The study included 140 participants from the Alzheimer’s Disease Neuroimaging Initiative (ADNI), comprising 43 cognitively normal (CN) individuals, 70 patients with mild cognitive impairment (MCI), and 27 with Alzheimer’s disease (AD). Eligible participants had comprehensive assessments of cognition, ASL, Apolipoprotein E4 (APOE4) genotyping, Polygenic Hazard Score (PHS) calculation, and amyloidosis indices. Data were analyzed using IBM SPSS ver. 20, employing chi-square, ANOVA, and linear regression models, with a significance threshold of P < 0.05.

Results

There were no statistically significant differences in demographic characteristics, including age, gender, and education level. Significant differences emerged in amyloid beta-protein 42 (Aβ42) levels, APOE4 status, and cognitive performance across groups. Four brain regions, including the left middle temporal, bilateral para-hippocampal, and right lingual cortex exhibited significant CBF differences (p < 0.05). Clinical Dementia Rating (CDR) correlated strongly with various brain regions, particularly in MCI individuals. Moreover, CBF in multiple regions showed significant associations with Aβ variants and their ratios, especially Aβ42, even after adjusting for confounding factors.

Conclusion

ASL demonstrates potential in predicting brain amyloidosis and monitoring AD. Significant associations between CBF and amyloid-beta levels suggest that ASL can detect early perfusion deficits related to AD progression.

查看原文本刊更多论文

动脉自旋标记在预测脑淀粉样变性中的潜在效用

背景：局部脑血流量（rCBF）下降在阿尔茨海默病中很常见。先前的研究表明，通过正电子发射断层扫描（PET）检测到的较高淀粉样蛋白β (Aβ)负荷与正常衰老个体的rCBF有关。本研究旨在评估动脉自旋标记（ASL）在预测脑淀粉样变性中的潜力。该研究纳入了来自阿尔茨海默病神经影像学倡议（ADNI）的140名参与者，包括43名认知正常（CN）个体，70名轻度认知障碍（MCI）患者和27名阿尔茨海默病（AD）患者。对符合条件的参与者进行认知、ASL、载脂蛋白E4 （APOE4）基因分型、多基因危险评分（PHS）计算和淀粉样变性指数的综合评估。数据采用IBM SPSS ver进行分析。20，采用卡方、方差分析和线性回归模型，显著性阈值为P <；0.05.结果两组患者年龄、性别、文化程度等人口统计学特征差异无统计学意义。淀粉样蛋白42 （a- β42）水平、APOE4状态和认知能力在两组之间存在显著差异。左侧中颞叶皮层、双侧海马旁皮层和右侧舌皮层四个脑区表现出显著的CBF差异(p <；0.05)。临床痴呆评分（CDR）与不同脑区密切相关，尤其是轻度认知损伤个体。此外，即使在调整了混杂因素后，多个区域的CBF也显示出与Aβ变异及其比率的显著关联，尤其是Aβ42。结论ASL在预测脑淀粉样变性和监测AD方面具有一定的应用价值。CBF和β淀粉样蛋白水平之间的显著相关性表明，ASL可以检测与AD进展相关的早期灌注缺陷。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Clinical Neuroscience 医学-临床神经学

CiteScore

4.50

自引率

0.00%

发文量

402

审稿时长

40 days

期刊介绍： This International journal, Journal of Clinical Neuroscience, publishes articles on clinical neurosurgery and neurology and the related neurosciences such as neuro-pathology, neuro-radiology, neuro-ophthalmology and neuro-physiology. The journal has a broad International perspective, and emphasises the advances occurring in Asia, the Pacific Rim region, Europe and North America. The Journal acts as a focus for publication of major clinical and laboratory research, as well as publishing solicited manuscripts on specific subjects from experts, case reports and other information of interest to clinicians working in the clinical neurosciences.